enGene Therapeutics Inc. · NASDAQ:ENGN

enGene Therapeutics — Technical Presentation (November 2026)

35 slides from enGene Therapeutics's technical presentation, Nov 12, 2026

  1. Slide 1: LEGEND Pivotal Cohort Interim Data Update

    LEGEND Pivotal Cohort Interim Data Update November 11, 2026

  2. Slide 2: Disclaimers: Cautionary Statement Regarding Forward-Looking Statements

    Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, and "forward-looking information" within the meaning

  3. Slide 3: Agenda

    Agenda 01 Welcome PRESENTER Ron Cooper Chief Executive Officer 02 New Interim Data Cohort 1: Detalimogene Without Surfactant PRESENTER Ashish Kamat, MD 03 NMIBC Market Insights PRESENTER Amy Pott Chief Global Commercialization Officer 04 Q&A ALL PRESENTERS MD Anderson November 2026: LEGEND Pivotal C

  4. Slide 4: Introductory Remarks

    Introductory Remarks

  5. Slide 5: Unlocking Community Practices: Unique Non-Viral Offering

    Unlocking Community Practices Unique Non-Viral Offering More treatment options are expected to increase sequencing which will expand treatable population Detalimogene non-viral approach provides a unique MOA for when doctors sequence therapies Low treatment burden for patients Simple storage and han

  6. Slide 6: LEGEND Principal Investigator Ashish Kamat, MD

    LEGEND Principal Investigator Ashish Kamat, MD Dr. Kamat is an Endowed Professor of Urologic Oncology and Cancer Research at MD Anderson Cancer Center and founding President of the International Bladder Cancer Group. Dr. Kamat specializes in genitourinary cancers, with a particular focus on immunoth

  7. Slide 7: No Winner Takes All: HR BCG-UR NMIBC Patients Need Multiple Options

    No “Winner Takes All”: HR BCG-UR NMIBC Patients Need Multiple Options Unmet Need Persists as No Current Therapy Meets All Patient Needs Bladder preservation Multiple options after persistence/recurrence may delay cystectomy, an invasive surgery with substantial morbidity. Tolerability Side effects d

  8. Slide 8: LEGEND: Multi-Cohort Study of Detalimogene In High-Risk NMIBC

    LEGEND: Multi-Cohort Study of Detalimogene In High-Risk NMIBC Treatment Schedule Phase 2: Ongoing Detalimogene 0.8 mg/mL (50 mL) IVI via catheter with 60-min dwell time2 Year 1 (induction) (Q12W) Re-induction at week 12 (persistent/ recurrent disease)3 Years 2-3 (maintenance) (Q12W) Week 1 2 3 4 5 6

  9. Slide 9: LEGEND Pivotal Cohort 1: Baseline Demographics and Disease Characteristics

    LEGEND Pivotal Cohort 1: Baseline Demographics and Disease Characteristics Characteristics Pivotal Cohort 1 (N=125) Age, years Median (Range) 71.0 (35.0-90.0) Sex, n (%) Female 24 (19%) Male 101 (81%) Race n (%) White 114 (91%) Asian 4 (3%) Black or African American 2 (2%) Not Reported 5 (4%) ECOG P

  10. Slide 10: Cohort Data: Detalimogene Without Surfactant

    Cohort 1 Data: Detalimogene Without Surfactant

  11. Slide 11: FDA Aligned Efficacy Evaluable Population

    FDA Aligned Efficacy Evaluable Population Alignment on Critical Items in Proposed Statistical Analysis Plan (SAP) 125 5 120 − = Trial patients Excluded from efficacy analysis Efficacy evaluable (EE) Patient 1 Did not have a post baseline disease assessment Patient 2 Did not have CIS within 1 year of

  12. Slide 12: Any Time Complete Response 56%

    Any Time Complete Response* 56% Detalimogene Without Surfactant Primary Endpoint: CR at Any Time Primary Endpoint in Range of Approved Products 91% of CRs occurred at first assessment& 100% of responders were free from progression to ≥T2 disease in the bladder 97% of EE patients were free from progr

  13. Slide 13: Duration of Response: Kaplan-Meier Estimate

    Duration of Response ≥ 12 months* (KM) 43% (CI: 30%, 55%) Key Secondary Endpoint: Kaplan-Meier Estimated Duration of Response Durability Trending Toward Approved Products, Assessments Ongoing *For durability assessments, 1 year is defined as 358 to 365+ days. Nine patients are pending their response

  14. Slide 14: Additional Supportive Data: CR Landmark 12 Months

    Endpoint Oct 2026 Apr 2026 Complete Response at 12 months, % (95% CI) 24% CI: 16%, 33% (n=110) 13% CI: 7%, 22% (n=98) Median Follow Up of Responders (Months) 12.0 (range: 3.7, 33.8) 9.2 (range: 3.7, 25.8) Additional Supportive Data: CR Landmark 12 months Endpoint Not Included in Approved Product Lab

  15. Slide 15: Detalimogene Demonstrated Favorable Safety and Tolerability Profile

    Detalimogene Demonstrated Favorable Safety and Tolerability Profile TRAEs were Generally Mild and Reversible, Consistent with Catheterization Participants with events n, (%) Pivotal Cohort 1 (N=125) ≥ 1 Treatment-related adverse event 59% Most frequent TRAEs (≥10%) Fatigue Dysuria Pollakiuria Bladde

  16. Slide 16: Detalimogene Compelling Efficacy and Tolerability Profile

    Detalimogene Compelling Efficacy and Tolerability Profile CR Any Time Rate DOR ≥12 months Rate^ KM for Detalimogene Lack of Dose Interruptions* Lack of Related Serious AEs* Detalimogene Approved Drugs Efficacy of Detalimogene vs. Approved Drugs Tolerability of Detalimogene vs. Approved Drugs * Detal

  17. Slide 17: Detalimogene Efficacy Profile has Meaningfully Improved

    Detalimogene Efficacy Profile has Meaningfully Improved Detalimogene has the potential to be a valuable treatment option for all patients *Fewer visits and pre- post-treatment precautions compared to BCG. Data is presented as available in the database as of 29October2026. Data Collection and Cleanin

  18. Slide 18: Commercial Opportunity

    Commercial Opportunity

  19. Slide 19: Detalimogene Go-to-Market Strategy

    Grounded in Where Care Happens & How Decisions are Made Detalimogene Go-to-Market Strategy Avoiding Cystectomy Settings of Care Shared Decision Making Treatment Options Redefining Care Pathway HR NMIBC is often “chronic” and highly recurrent - patients will do anything to avoid cystectomy 75% of HR

  20. Slide 20: Vision: Detalimogene to Redefine Care in Community Practices

    Vision: Detalimogene to Redefine Care in Community Practices 01 Clinical value A meaningful and tolerable bladder-sparing option for all patients, supported by a differentiated non-viral MOA profile. 02 Practice value Economic value Potential for favorable net cost recovery with manufacturer support

  21. Slide 21: Urology Segment NMIBC Patients

    Urology Segment NMIBC Patients 19% (~3,800) 11% (~2,200) 11% (~2,200) 6% (~1,200) 29% (~5,800) Academic Medical Center 24% (~4,800) Note: Assumes ~20,000 addressable NMIBC BCG-unresponsive patients. Resource-Limited, Workflow-Constrained, Economics-Focused, and Clinical-Excellence all represent urol

  22. Slide 22: Urology Segment NMIBC Patients: Shared Decision Making

    Urology Segment NMIBC Patients 19% (~3,800) 11% (~2,200) 11% (~2,200) 6% (~1,200) 29% (~5,800) Academic Medical Center 24% (~4,800) Note: Assumes ~20,000 addressable NMIBC BCG-unresponsive patients. Resource-Limited, Workflow-Constrained, Economics-Focused, and Clinical-Excellence all represent urol

  23. Slide 23: High Risk NMIBC is a Long Journey

    High Risk NMIBC is a Long Journey Trusted Urologist-Patient Relationship Built Over Time to Maintain Treatment Goals 2. Avoiding Cystectomy 1. Settings of Care 3. Share Decision Making 4. Treatment Options 5. Redefining Care Pathway JAN 2024 | INITIAL PRESENTATION June 2025 | RECURRENCE JULY 2025 -

  24. Slide 24: Treatment Selection Guided by Patient Priorities and Practice Capabilities

    Treatment Selection Guided by Patient Priorities and Practice Capabilities No Winner Takes All – Patients and Urologists Consider Many Factors First, understand the patient and the practice, then, discuss all options Treatment Burden Weigh visit frequency, doses, and duration against the patient's d

  25. Slide 25: Detalimogene's Profile Aligns with Key Treatment Considerations

    Detalimogene’s Profile To Date Aligns with Key Treatment Considerations Treatment Burden Shorter treatment time (1hr vs. 2hr dwell) and fewer doses (4 vs. 6) in 12-week cycle than required for BCG Efficacy Unique MOA with complete response rate at any time and duration of response similar to approve

  26. Slide 26: Detalimogene is a Potential Low Burden & Convenient Option

    Detalimogene is a Potential Low Burden & Convenient Option for Patients Treatment Time Dosing Schedule (First 3 Months) Keytruda Adstiladrin Anktiva + BCG Inlexzo Cretostimogene 60 minutes IVI treatment dwell 30min IV infusion 48hr urine bleaching 60min IVI treatment dwell 25min to 5hr vial thaw 6hr

  27. Slide 27: A Future Where Recurrent NMIBC Patients Can Keep Their Bladders Longer

    A Future Where Recurrent NMIBC Patients Can Keep Their Bladders Longer Patients will Sequence Therapies Resulting in Enhanced Long-Term Care Note: Interviews n=22 urologists. The rate of patients requiring a 3L/4L therapy could be anywhere from 75% - 35% depending on which therapy they receive and r

  28. Slide 28: Sequencing & Shared Decision Making Creates a New Care Pathway

    2. Avoiding Cystectomy 1. Settings of Care 3. Share Decision Making 4. Treatment Options 5. Redefining Care Pathway 2024 2025 2026 Sequencing & Shared Decision Making Creates a New Care Pathway 2030+ JAN 2024 | INITIAL PRESENTATION June 2025 | RECURRENCE JULY 2025 - NOV 2025 Gem/doce induction IVI ×

  29. Slide 29: NCCN Guideline 2A Dictates Payer Coverage at New Price Point

    NCCN Guideline 2A Dictates Payer Coverage at New Price Point Interviewed Payers Cover Therapies at Parity at New Price Point Assuming Category 2A Note: WAC = wholesale acquisition cost. Keytruda®, Adstiladrin®, Anktiva®, Inlexzo® are trademarks of their respective owners. New price point assumes pri

  30. Slide 30: Vision: Detalimogene to Redefine Care in Community Practices

    Vision: Detalimogene to Redefine Care in Community Practices 01 Clinical value A meaningful and tolerable bladder-sparing option for all patients, supported by a differentiated non-viral MOA profile. 02 Practice value Economic value Potential for favorable net cost recovery with manufacturer support

  31. Slide 31: Segmentation and Value Pillars Inform Field Force Deployment

    Segmentation and Value Pillars Inform Field Force Deployment ~11,000 Bladder Cancer Urologists Academic Medical Center Health System / Hospital Clinical Excellence Practices Economics-Focused Practices Workflow-Constrained Practices Resource-Limited Practices ~14,600 Practicing Urologists Field Forc

  32. Slide 32: Value Pillars Inform enGene Commercialization Strategy

    Value Pillars Inform enGene Commercialization Strategy Practice Value Patient Value Economic Value Clinical Value DETALIMOGENE HYPOTHESIS Commercial potential is driven by our broad alignment to the needs of all urologists Clear Differentiation Evaluation of precise and efficient field organization

  33. Slide 33: Closing Remarks

    Closing Remarks

  34. Slide 34: Detalimogene: Next Gen NMIBC Treatment Designed for Community Use

    Detalimogene: Next Gen NMIBC Treatment Designed for Community Use Large Total Addressable Market Differentiated Total Product Profile Lifecycle Management Near-Term Planned Catalysts NMIBC market forecasted to be >$20B Surfactant Bladder Rinse has Potential to Improve Efficacy, Duration of Response

  35. Slide 35: Thank You

    Thank You

enGene Therapeutics — Technical Presentation (November 2026) on 6ix